Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTIST-CKD
NL-OMON61060Phase 2Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Survodutide with Placebo (2 arms). Primary endpoint: Percentage change from baseline to week 32/36 in first morning void UACR. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON61060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61060.